18 May 2016
Insulin trial disappoints; strong progress in oncology
Midatech has released an update on several of its development programmes. Although the Phase IIa trial of Midaform Insulin Pharmfilm® failed to replicate the promising PK profile seen in earlier trials, good progress has been reported in Midatech’s core oncology programmes (MTR103 and MTR104) and the ongoing compassionate use programme in paediatric brain cancer. We have removed Midaform Insulin from our valuation but increased our expectations for MTR103 and MTR104. Our revised target price sta ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Insulin trial disappoints; strong progress in oncology
- Published:
18 May 2016 -
Author:
Dr Jens Lindqvist -
Pages:
3
Midatech has released an update on several of its development programmes. Although the Phase IIa trial of Midaform Insulin Pharmfilm® failed to replicate the promising PK profile seen in earlier trials, good progress has been reported in Midatech’s core oncology programmes (MTR103 and MTR104) and the ongoing compassionate use programme in paediatric brain cancer. We have removed Midaform Insulin from our valuation but increased our expectations for MTR103 and MTR104. Our revised target price sta ....